Spain Glp-1 Receptor Agonist Market Size & Outlook
Spain glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Spain glp-1 receptor agonist market highlights
- The Spain glp-1 receptor agonist market generated a revenue of USD 377.4 million in 2023 and is expected to reach USD 1,869.9 million by 2030.
- The Spain market is expected to grow at a CAGR of 25.7% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 377.4 million |
| Market revenue in 2030 | USD 1,869.9 million |
| Growth rate | 25.7% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Spain accounted for 1.0% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 48.78% in 2023. Horizon Databook has segmented the Spain glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
Spain’s pharmaceutical sector has been receiving major investments, which are anticipated to positively influence the GLP-1 receptor agonist market. The country has a high prevalence of target diseases, which drives the market further.
For instance, according to the International Diabetes Federation, diabetes prevalence in Spain is around 14.8%, accounting for 5.1 million people with diabetes in the country. Spain’s supportive healthcare policies & initiatives to increase public awareness and monitor the disease rate are expected to increase the demand for GLP-1 receptor agonist drugs in the market.
According to the Global Competitiveness 2020 Report, the World Economic Forum nominated Spain as the country with the world's best healthcare system. Key players in the market are adopting strategies like collaborations, product launches, and acquisitions to maintain their positions.
Reasons to subscribe to Spain glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Spain glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Spain glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Spain glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Spain GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
